Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that the FDA has lifted the clinical hold on two phase I trials of its candidate, vadastuximab talirine (SGN-CD33A; 33A).
GlaxoSmithKline's Nucala Positive in Label Expansion Study
by Zacks Equity Research
GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints.
Adaptimmune Therapeutics (ADAP) Jumps: Stock Rises 10.5%
by Zacks Equity Research
Adaptimmune Therapeutics plc (ADAP) shares rose over 10% in the last trading session.
Nabriva Therapeutics (NBRV) Catches Eye: Stock Gains 9.8%
by Zacks Equity Research
Nabriva Therapeutics AG (NBRV) moved big last session, as its shares rose almost 10% on the day.
New Strong Buy Stocks for March 3rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Incyte Treats First Patient in Phase II GVHD Study on Jakafi
by Zacks Equity Research
Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.
Abbott Labs to Close St. Jude Acquisition Later this Week
by Zacks Equity Research
Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.
Immunomedics Completes Enrollment In Cancer Drug Study
by Zacks Equity Research
Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate
by Zacks Equity Research
Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
by Zacks Equity Research
Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).
Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout
by Zacks Equity Research
Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).
McKesson (MCK) Closes Rexall Health Acquisition in Canada
by Zacks Equity Research
McKesson Corporation (MCK) announced that it has completed the acquisition of Canada-based Rexall Health for $2.1 billion
ImmunoGen: Phase I Data on Ovarian Cancer Drug Published
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.
Achillion Receives $15M from J&J for HCV Study Enrolment
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.
Amphastar Stock Down on CRL for Asthma Drug in the U.S.
by Zacks Equity Research
Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).
Shire Gets FDA Approval for Label Expansion of Adynovate
by Zacks Equity Research
Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age
Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
by Zacks Equity Research
Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.
Neothetics (NEOT) Begins Phase II Study on Lead Candidate
by Zacks Equity Research
Neothetics, Inc. (NEOT) announced that it has commenced a phase II proof-of-concept study, LIPO-202-CL-31, on its lead candidate, LIPO-202, for the reduction of submental subcutaneous fat.
Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold
by Zacks Equity Research
Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.
Horizon's Rare Disease Drug Quinsair Launched in Canada
by Zacks Equity Research
Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.
Synergy Reports Positive Top-Line Phase III Data on IBS Drug
by Zacks Equity Research
Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients suffering from irritable bowel syndrome.
Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.
Aerie (AERI) Rhopressa Regulatory Application Delayed Again
by Zacks Equity Research
Aerie (AERI)'s NDA for lead candidate, Rhopressa, gets delayed again due to delay on the manufacturer's part.
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).
Celgene's Otezla Gains Positive Recommendation from NICE
by Zacks Equity Research
Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.